TCGA-AR-A24P-01A-11R-A169-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 3
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- MITOTIC_SPINDLE+0.360
- PROTEIN_SECRETION+0.350
- TGF_BETA_SIGNALING+0.300
- G2M_CHECKPOINT+0.290
- HEDGEHOG_SIGNALING+0.280
- ESTROGEN_RESPONSE_EARLY+0.270
- APOPTOSIS+0.210
- ANDROGEN_RESPONSE+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.460
- FATTY_ACID_METABOLISM-0.310
- MYC_TARGETS_V2-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- DNA_REPAIR-0.260
- XENOBIOTIC_METABOLISM-0.240
- ADIPOGENESIS-0.210
- UV_RESPONSE_UP-0.190
- ALLOGRAFT_REJECTION-0.170
- INTERFERON_ALPHA_RESPONSE-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-7726-01A-11R-2170-07 | — | cohortSQ1 | 0.818 |
| 2 | TCGA-E9-A226-01A-21R-A157-07 | — | B | 0.784 |
| 3 | SRR4195679 | — | — | 0.784 |
| 4 | TCGA-AR-A24L-01A-11R-A169-07 | — | B | 0.783 |
| 5 | f5e6497a-ed39-408d-9034-a965baaafbf7 | — | — | 0.782 |
| 6 | MNG435 | — | — | 0.779 |
| 7 | TCGA-85-A50M-01A-21R-A262-07 | — | cohortSQ1 | 0.775 |
| 8 | TCGA-B6-A0IM-01A-11R-A034-07 | — | B | 0.769 |
| 9 | TCGA-AR-A24M-01A-11R-A169-07 | — | B | 0.757 |
| 10 | TCGA-HD-7753-01A-11R-2081-07 | — | — | 0.754 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.170 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |